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Abstract: The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family and 
are activated by environmental stress. JNK is also activated by proinflammatory cytokines, such as TNF and IL-1, and 
Toll-like receptor ligands. This pathway, therefore, can act as a critical convergence point in immune system signaling for 
both adaptive and innate responses. Like other MAPKs, the JNKs are activated via the sequential activation of protein 
kinases that includes two dual-specificity MAP kinase kinases (MKK4 and MKK7) and multiple MAP kinase kinase 
kinases. MAPKs, including JNKs, can be deactivated by a specialized group of phosphatases, called MAP kinase 
phosphatases. JNK phosphorylates and regulates the activity of transcription factors other than c-Jun, including ATF2, 
Elk-1, p53 and c-Myc and non-transcription factors, such as members of the Bcl-2 family. The pathway plays a critical 
role in cell proliferation, apoptosis, angiogenesis and migration. In this review, an overview of the functions that are 
related to rheumatic diseases is presented. In addition, some diseases in which JNK participates will be highlighted. 
Keywords: Signal transduction, inflammation, autoimmunity, rheumatoid arthritis. 
INTRODUCTION 
 The c-Jun N-terminal kinases (JNKs) are members of a 
larger
 
group of serine/threonine (Ser/Thr) protein kinases 
known as the mitogen-activated protein kinase (MAPK) 
family [1]. The classical JNK pathway is activated following 
the exposure of cells to extracellular stresses, such as UV 
irradiation, hyperosmolarity, and heat shock [2]. The range 
of initiating signals has been expanded
 
to include a diversity 
of stimuli. Of particular interest is the activation of the JNK 
pathway following the exposure to some proinflammatory 
cytokines, such as tumor
 
necrosis factor-? (TNF) and 
interleukin-1 (IL-1) [3]. The JNK pathway also contributes 
to innate immune response following ligation of 
various
 
Toll-like receptors (TLR) [4]. The JNK pathway 
therefore acts as a critical intermediate and convergence 
point in immune system signaling [3]. 
 The mammalian JNKs are encoded by three distinct 
genes (Jnk1,
 
Jnk2, and Jnk3) [1]. Additional complexity is 
generated by alternative splicing, which results in up to 10 
different
 
protein products varying in size from 46 kDa to 56 
kDa [5]. Sequence alignment of these different products 
shows homologies of >80%. This similarity initially 
suggested that the JNK proteins perform similar roles, with 
an equivalent ability to bind to various upstream activators 
and downstream substrates. However, additional complexity 
results from variable tissue distributions of JNK expression. 
JNK1 and JNK2 isoforms are ubiquitously expressed, while 
JNK3 is almost exclusively found in the brain, heart 
and testis [1]. This observation initially reinforced the idea of 
a specific role for JNK3 in neurons, whereas there might be 
redundant actions of JNK1 and JNK2 in other tissues. Yet, 
increasing evidence supports JNK isoform-specific roles [6]. 
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 Analogous to other MAPKs, JNKs are activated via the 
sequential activation of protein kinases that includes two 
dual-specificity MAP kinase kinases (MKK4 and MKK7) 
and multiple MAP kinase kinase kinases (MKKKs) such as 
ASK1, MEKK1-4, TAK1-3 or MLK1-3, depending on the 
cell lineage and the type of stimulus [2, 7] (see Fig. 1). The 
MKKKs phosphorylate and activate MKK4 and MKK7, 
which, in turn activate JNKs by dual phosphorylation. 
MKK4 is primarily activated by environmental stress and 
preferentially phosphorylates tyrosine (Y) residue 185 in the 
JNK1 activation motif (TPY), whereas MKK7, which is 
primarily activated by cytokines (TNF and IL-1), preferen-
tially phosphorylates threonine (T) residue 183. While 
MKK7 is a specific activator of JNKs, MKK4 can also 
phosphorylate p38 MAPKs under some circumstances [8]. 
 MAPKs, including JNKs, can be deactivated by a 
specialized group of phosphatases, called MAP kinase 
phosphatases (MKPs)  [2]. The MKPs are a subgroup of the 
protein tyrosine phosphatase (PTP) family with specificity 
for phosphotyrosine and phosphothreonine residues in the 
MAPK activation loop. Several MKPs, including: MKP-1, 
MKP-3, MKP-5 and MKP-7 can inactivate JNK  [2]. Like 
other PTPs, MKPs contain a highly reactive cysteine, that 
mediate their enzymatic function, offering a way to regulate 
MAPK activity in response to production of reactive oxygen 
species (ROS) or exposure to thiol-reactive compounds. 
MicroRNA (miRNA) can also regulate MPKs. For instance, 
miR-101 targets MKP-1 and can regulate JNK activation in 
macrophages after LPS stimulation [9]. 
 After JNKs are activated, they subsequently 
phosphorylate a variety of substrates that regulate a wide 
range of cellular functions [4]. The JNKs were originally 
identified by their ability to phosphorylate both Ser63 and 
Ser73 within the transactivation domain of the transcription 
factor c-Jun, which potentiates its transcriptional activity 
[10]. Dimerization with other Jun family members (Jun, 
JunB and JunD), Fos or activating transcription factor (ATF) 
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family members comprise the transcription factor activator 
protein 1 (AP-1), which regulates a broad variety of genes by 
binding to their promoter and enhancer regions [11]. 
Through AP-1, JNK also regulates miRNA expression 
including miR-155 [12-15], known to be overexpressed in 
RA synoviocytes [16] and to have critical immune regulatory 
functions [15]. JNK phosphorylates and regulates the activity 
of transcription factors other than c-Jun, including ATF2, 
Elk-1, p53 and c-Myc and non-transcription factors, such as 
members of the Bcl-2 family [4]. Interactions with these 
nuclear and nonnuclear substrates shed light on the multiple 
functions of JNKs. For instance, JNKs play a role in 
cytokine production and extracellular matrix regulation 
through production of matrix metalloproteinases (MMP) 
[17]. JNKs functions also involve cell proliferation [11], 
apoptosis [18], angiogenesis [19] and migration [20]. In this 
review, an overview of the functions that are related to 
rheumatic diseases is presented. In addition, some diseases in 
which JNK participates will be highlighted. 
JNK AND MMP REGULATION 
 MMP are a family of structurally and functionally related 
zinc-containing endopeptidases that can degrade almost all 
of the components of the extracellular matrix (ECM) [21, 
22]. Based on their structures, sequence similarities and 
substrate specificities, they are often classified into several 
different subgroups [21, 22]. Collagenases (MMP-1 and 
MMP-13) that cleave the native collagen and stromelysins 
(MMP-3, MMP-10, MMP-11) have broad substrate 
specificity for proteoglycans, fibronectin and laminin and are 
perhaps the most important for bone/cartilage degradation. 
Maintaining equilibrium between deposition and degradation 
of the ECM is essential to normal tissue development, 
wound repair and tissue damage due to inflammation. In 
different pathological states such as inflammatory arthritis 
and osteoarthritis (OA), degradation is disproportionately 
increased with the concurrent disequilibrium [23]. 
 MMP gene expression is primarily regulated at the 
transcriptional level [21, 22]. Inflammatory cytokines such 
as IL-1, TNF, TLR ligands, and growth factors are primary 
drivers of gene expression in most cell types [24]. Several 
transcription factors are involved in MMP gene regulation, 
especially activator protein-1 (AP-1)  [21]. Inflammatory 
cytokines enhance MMP gene expression through the 
MAPK signaling pathway, by increasing the levels and 
phosphorylating different AP-1 components, such as c-Jun, 
JunB and c-Fos [21]. Epigenetic mechanisms, such as DNA 
methylation or histone acetylation, can also contribute to 
MMP regulation. Likewise, post-transcriptional regulatory 
processes including mRNA stability, protein translational 
efficiency, and miRNA-based mechanisms modulate MMP 
gene expression [21]. Recently, aberrant posttranscriptional 
regulation of MMPs by miRNA has emerged as an important 
factor in human diseases, including OA and rheumatoid 
arthritis (RA)  [25]. 
 The role of JNK in MMP regulation has been confirmed 
in cancer development, tumor cell invasion, and in 
fibroblast-like synoviocytes (FLS) [22]. Elevated JNK1 
expression might contribute to increased MMP activity and 
ECM invasion by tumor cells, and also plays a major role in 
MMP induction in RA synoviocytes [22]. The critical role of 
JNK in MMP regulation in FLS was confirmed using small 
molecule inhibitors and JNK knockout synoviocytes in 
which MMP3 and MMP13 expression was significantly 
decreased compared to control FLS after IL-1 stimulation 
[17, 26]. RNA interference studies showed that only MKK7 
is required for IL-1, TNF, TLR2 and TLR4 ligand-mediated 
JNK activation and MMP expression in cultured RA FLS, 
while TLR3 requires both MKK4 and MKK7 [27, 28]. After 
TLR3 stimulation, alternative pathways are also involved, 
Fig. (1). The mitogen activated protein [MAP] kinase signalling pathways. The MAPK pathways include three main families 
(extracellular regulating kinases, c-Jun N-terminal kinases, and p38) that form an integrating and amplifying cascade of 3 kinase tiers. JNKs 
are activated via the sequential activation of protein kinases that includes two dual-specificity MAP kinase kinases (MKK4 and MKK7) and 
multiple MAP kinase kinase kinases (MKKKs) such as ASK1, MEKK1-4, TAK1-3 or MLK1-3. The top level shows the MKKKs, the 
second tier shows the MKKs, and the third tier consists of the MAP kinases. Each pathway activates a variety of transcription factors that 
regulate genes involved with cell survival, proliferation, and inflammation. There is considerable overlap of the genes regulated by the 
individual MAPKs. Gadd45ß is shown as a negative regulatory mechanism that suppresses JNK by blocking MKK7. ASK, apoptosis signal 
regulating kinase; ATF, activating transcription factor; IL, interleukin; MAPKAP, MAPK activated protein; MEKK, MKK kinase; TAK, 
TGF? associated kinase. 
MEKK1 MEKK4       MEKK2   TAK1  ASK1  MLK3           MEKK3  MEKK6 
MEK1/2                       MKK4  MKK7                                   MKK3    MKK6 
ERK1/2                            JNK1/2/3          Gadd45ß                 p38 
EIk-1 
c-Myc 
                                
         migration   MMPs, cytokines,  
                                              VEGF, apoptosis 
                                                 
paxillin    c-Jun (AP-1)        NF-kB             ATF2, Elk-1,         
             MAPKAPK2 
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such as IKK?, which can phosphorylate c-Jun in cultured 
FLS [29, 30]. The IKK-related kinase pathway could 
synergize with JNK by providing two parallel mechanisms 
for AP-1 activation. This also provides a novel link between 
antiviral responses, innate immunity, and destruction of the 
extracellular matrix in RA as TLR3 ligands have been 
identified in rheumatoid synovial effusions [31]. Finally, IL-
1?-induced JNK activation also decreases expression of 
miR-27b, an miRNA that correlates with an increase of the 
MMP13 expression in chondrocytes [32]. 
 Loss of articular cartilage integrity and synovial 
inflammation are key features of RA and OA  [33, 34]. The 
results in genetically-modified mice, however, do not clearly 
support a role of MMP in extracellular matrix destruction in 
those diseases [35]. For instance, MMP3-deficient mice have 
either no difference in disease severity or paradoxical 
acceleration of disease in RA and OA models [36-39]. In 
addition, MMP inhibitors have generally been ineffective in 
RA and OA for clinical signs and symptoms and disease 
progression [40]. While an effect on MMP expression might 
contribute to potential benefit of a JNK inhibitor in arthritis, 
additional functions as described below will probably be 
needed. 
JNK AND CYTOKINE REGULATION 
 Chronic inflammatory and autoimmune diseases, such as 
RA, psoriatic arthritis (PsA), systemic lupus erythematosus 
(SLE) or inflammatory bowel disease, are exemplified by 
imbalances in pro- and anti-inflammatory cytokines for 
induction of autoimmunity, inflammation and tissue damage. 
The cytokine milieu together with immune cell infiltration 
plays a key role in disease initiation and perpetuation. For 
example, TNF, IL-1, and IL-6 contribute to RA by 
increasing synovial production of chemokines, cytokines, 
MMPs and
 
adhesion molecules, thereby further enhancing 
cell infiltration, inflammation and
 
cartilage destruction [41, 
42]. TNF, IL-1, IL-6 and IL-17 activate
 
all three MAPK 
families (JNK, p38 MAP kinase, and extracellular regulating 
kinase (ERK)) in synovial fibroblasts [41-43], and TNF and 
IL-1 also activate ERK, JNK and
 
p38 MAPK in 
chondrocytes [42]. The JNK pathway is also engaged in 
macrophages following ligation of TLRs, leading to cytokine 
production. 
 While many studies describe the activation of JNK 
through AP-1 in several cell types and AP-1 [44], less is 
known about the specific contribution of the JNK1 or JNK2 
isoforms to cytokine regulation. For instance, JNK plays an 
important role in Tnfa gene transcription  [45]. The Tnfa 
gene, which encodes TNF, contains JNK-responsive 
promoter elements required for normal Tnfa gene expression, 
including an AP-1 site that selectively binds heterodimeric 
complexes of ATF2 and c-Jun [46]. JNK can also 
phosphorylate ATF2 and c-Jun leading to increased 
transcription activity [1]. Only combined JNK1/2-deficient 
cells and not the single knockout cell, exhibit a severe defect 
in Tnf? mRNA expression [45, 47], suggesting redundant 
actions of JNK1 and JNK2 in TNF regulation. Although 
some reports suggest that JNK could also be involved in 
post-translational regulation of cytokines, direct mechanistic 
links between JNK and mRNA stability or translation remain 
elusive [48]. 
JNK AND APOPTOSIS AND CELL PROLIFERATION 
 JNKs are involved in cell proliferation, differentiation, 
survival, and programed cell death (apoptosis) [11, 49, 50]. 
The role of JNKs in the cellular decision to increase 
proliferation or cell deletion through apoptosis depends on 
the stimulus and the cell type  [50, 51]. Sustained activation 
of JNK is usually associated with apoptosis, whereas the 
acute and transient activation of JNK may be involved in cell 
proliferative or survival pathway [49]. 
 Signaling pathways that initiate apoptosis have been 
broadly classified into extrinsic pathways initiated by death 
receptors such as those of TNF, TRAIL and FAS-L, and 
intrinsic pathways initiated by mitochondrial events [52]. 
JNK has been observed to have a central role in both of these 
pathways. Numerous studies shows that the JNK-AP-1 
pathway can stimulate expression of pro-apoptotic genes 
such as TNF and Fas-L. JNK also decreases the expression 
of pro-survival genes such as Bcl-2, Bcl-x and BAD, through 
multiple transcription factors in cell type- and stimuli-
specific manner. The crosstalk between NF-?B and JNK 
pathways is also critical in TNF-induced cellular signalling 
pathways, which ultimately determines whether a cell lives 
or dies [49-51]. 
 Apoptosis plays a critical role in many biological 
processes, such as embryonic development, immune 
responses, tissue homeostasis and normal cell turnover. For 
instance, apoptosis plays a central role in the immune system 
in the maintenance of self-tolerance and homeostatic control 
of lymphocyte populations [53]. Lymphocyte death is tightly 
controlled and there are potentially dangerous consequences 
when this control is abdicated, including autoimmunity. 
Among its many functions, JNK has a role in thymocyte 
negative selection, probably through c-Jun phosphorylation 
[3]. In the periphery, JNK might also be involved in cell 
death regulation during activation-induced cell death. JNK1 
deficient T cells exhibit greater proliferation, which is 
associated with reduced activation-induced cell death [3]. 
This result suggests that JNK1 regulates apoptosis in T cells, 
as it does in other systems, although how JNK1 works has 
not been established. 
 Interestingly, JNK is not simply a proapoptotic protein 
kinase. It is activated by a variety of extracellular stimuli, 
only some of which induce apoptosis [50]. Evidence has 
been accumulating in certain tumors suggesting the 
involvement of JNK in cell survival or antiapoptosis. The 
molecular mechanism by which JNK suppresses 
programmed cell death is incompletely understood, although 
JNK may only exert its pro-survival function in p53-
deficient cells [54]. 
JNK AND T HELPER CELL DIFFERENTIATION 
 Although only very low expression of JNK1 and JNK2 
genes and their upstream kinases can be detected in naive 
CD4
+
 and CD8
+
 T cells  [55, 56], they are induced upon 
activation through the TCR and, most likely, a combination 
of cytokines [55, 57]. After their induction in CD4
+
 T cells, 
JNK1 and JNK2 are involved in the cellular differentiation 
into effector T-helper 1 (Th1) and Th2 cells [3]. The 
expression of JNK1 and JNK2 in either Th1 or Th2 cells is 
similar and is much higher than naive CD4
+
 T cells. JNK 
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activity can be rapidly induced in effector Th1 cells, but 
minimal JNK activity is detected in effector Th2 cells, 
suggesting that JNK might have a more important role in 
Th1 cells [57]. JNK1-deficient mice exhibit deficient Th1 
differentiation and exaggerated Th2 responses [57]. Th2 
differentiation and IL-4 production by CD4
+
 T cells from 
JNK2-deficient mice is normal, but Th1 differentiation and 
interferon-? (IFN-?) production is also impaired [58]. Other 
reports also suggest JNK involvement in T helper cell 
differentiation. MKP-7, which preferentially inactivates 
JNK, is induced during Th2 differentiation [59]. JNK also 
plays a role in IL-32-dependent maturation and activation of 
dendritic cells (DCs), leading to enhanced Th1 and Th17 
responses as the result of increased IL-12 and IL-6 
production in DCs [60]. 
 Taken together, these data suggest that the role of JNK in 
T cell immune responses is to reduce proliferative responses 
of the activated THz cells and to potentiate polarized T cell 
differentiation into the Th1 and perhaps Th17 lineage  [3]. 
JNK inhibition, therefore, could be an interesting candidate 
to treat Th1-mediated diseases. Although JNK1-deficient 
CD4 T cells have defective T cell activation or 
differentiation in vitro and JNK-dependent B-cell maturation 
and immunoglobulin production are regulated through miR-
155  [13], the absence of JNK1 in T and B cells does not 
alter their ability to mount a pathogenic autoimmune 
response to myelin [61] or methylated bovine serum albumin 
(mBSA) [62]. The reasons for such differences are unclear, 
but possible explanations include the stimulation method and 
the complexity of an in vivo environment. 
JNK AND CELL MIGRATION 
 Cell movement is a complex biological process requiring 
coordinated
 
changes in the activities of numerous protein 
complexes, including actin polymerization, adhesion 
dynamics, and changes in cell polarity [63]. A number of 
focal adhesion, microtubule-associated and intermediate 
filament proteins (for instance, paxillin, keratin-8, tau or 
kinesin) are JNK substrates [4]. One of them, paxillin, was 
proposed as a JNK substrate based on its localization
 
in focal 
adhesions and it has been studied more extensively [20]. 
JNK-mediated phosphorylation of paxillin is likely a key 
event in the regulation of migration of many cell types such 
as fibroblasts and cancer cells. JNK1 is also involved in 
macrophage migration  [62]. 
JNK AND ANGIOGENESIS 
 Angiogenesis is a highly coordinated tissue remodelling 
process leading to blood vessel formation. Formation of new 
blood vessels plays an important role in the pathogenesis of 
rheumatic diseases, including RA and PsA, as well as 
malignancy and ocular angiogenic diseases [64-66]. The 
extent of synovial inflammation and subsequent joint 
destruction requires the formation of new blood vessels. 
Vascular endothelial growth factor (VEGF) plays a key role 
in angiogenesis associated with inflammation [67] and was 
detected in synovial fluids and tissue from RA and PsA 
patients, correlating with disease activity, severity and joint 
involvement [68, 69]. Hypoxia through the hypoxia-
inducible factor (HIF) [70], and pro-inflammatory cytokines, 
such as TNF and IL-1 stimulate various cell types in the 
synovium, including macrophages, fibroblasts, vascular 
smooth muscle cells and synovial lining cells to release 
VEGF [71, 72]. Numerous other mediators including IL-6, 
IL-17, IL-18, nitric oxide (NO), and prostaglandins act 
indirectly on angiogenesis by promoting VEGF production 
[64]. 
 Given the multiple roles of VEGF in regulation of 
vascular biology, it is not surprising that expression of this 
protein is tightly regulated [73]. We recently showed that 
another important factor involved in VEGF induction is 
JNK1 [19]. Mice lacking JNK1 exhibit reduced pathological 
angiogenesis and lower levels of retinal VEGF production in 
a murine model of retinopathy of the prematuity (see Fig. 2). 
This data indicated that JNK1 is a critical factor in hypoxia-
induced retinal VEGF production and pathological ocular 
angiogenesis. Retinal JNK-dependent VEGF expression 
occured independently of HIF activation, and hypoxia 
stimulated JNK activity through ROS production. Once 
activated, JNK induced c-Jun phosphorylation at the VEGF 
promoter. 
 Other factors such as PDGF, angiopoietin/Tie2 and Fak 
pathways are also critically important in angiogenesis, and 
are highly expressed in synovial tissue [74, 75]. These 
pathways are involved in vessel stabilization and 
neoangiogenesis, and their interaction with VEGF is critical 
for vessel morphology and stability  [76-78]. For instance, 
the formation of capillary-like structures during angiogenesis 
requires events that allow endothelial cells and pericytes to 
migrate into the perivascular space. FAK plays a central role 
in modulating endothelial and vascular smooth muscle cells 
migration  [78]. Tie2 activation by angiopoietin promotes 
vessel assembly and maturation by mediating survival 
signals for endothelial cells and regulating the recruitment of 
mural cells [79]. JNK has been implicated in these pathways, 
suggesting that its role of JNK in angiogenesis goes beyond 
VEGF regulation [80, 81]. 
JNK AND RHEUMATOID ARTHRITIS 
 RA is a chronic autoimmune disease in which the 
importance of pro-inflammatory cytokines has been 
confirmed by the success of biologics that block TNF, IL-
1
 
or IL-6. However, there remains a clinical
 
need for new 
therapies, as individual regimens are only effective in
 
a 
proportion of patients. Moreover, their high cost and need 
for parenteral administration have led to alternative strategies 
such as orally active small molecule. This approach could 
target key intracellular signaling molecules that regulate both 
cytokine production and cytokine action, affecting more than 
one cytokine or cytokine receptor. 
 JNK activation in RA. JNKs and its upstream kinases 
(MKK4 and MKK7) are highly activated in isolated RA FLS 
and in the rheumatoid synovial lining layer and synovial 
mononuclear cell infiltrates [17, 43, 82, 83]. Western blot 
analysis in cultured synoviocytes reveals 46 and 54 kDa 
species. JNK2 appears to be the dominant isoform in FLS, 
accounting for about 90% of the total JNK protein. 
Downstream, components to the AP-1 complex, c-Jun and c-
Fos, are also expressed both in the synovial lining and 
sublining layer. 
 The JNK pathway in animal models. The activation and 
function of JNK has been extensively characterized in 
several animal models of arthritis, including passive K/BxN 
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arthritis and collagen-induced arthritis (CIA) [84]. In the 
passive model, synovial JNK activation occurs within 1 day 
after injection with arthritogenic serum and before clinical 
arthritis occurs. Both 46 and 54 kDa isoforms are 
phosphorylated, peak before maximum clinical arthritis, and 
decline toward baseline by day 12. The kinetics of JNK 
activation parallels MMP3 gene expression in the joint.  
P-MKK4 and –c-Jun are also detected and actually reach 
their highest level later in the model (day 8). The results for 
CIA are strikingly different. Only the 54 kDa isoform is 
phosphorylated (unlike RA and passive K/BxN arthritis), 
which begins by day 10 after immunization and peaks on day 
30 when MMP3 expression is also highest. Thereafter,  
P-JNK levels rapidly decline to baseline levels (see Fig. 3). 
The timing and isoform selectivity of each model needs to be 
considered when evaluating the potential therapeutic agents 
that target JNK. 
 Several reports suggest a critical role of JNK in 
inflammatory arthritis. Interference with AP-1 decoy 
oligonucleotides or using c-Fos/AP-1 inhibitors decreases 
severity of CIA accompanied by suppressing inflammatory 
cytokine and MMP synthesis, thus confirming the critical 
role of AP-1, and presumably JNK, in joint inflammation 
[85]. A JNK1/2 inhibitor, SP600125, was mildly anti-
inflammatory in the rat AIA but it conferred striking 
protection against bone and cartilage destruction, together 
with a decrease of the collagenase (MMP-13) gene, 
confirming the role of JNK in arthritis [17]. In another 
 
Fig. (2). JNK1 regulates VEGF expression and neo-vascularization in a murine model of retinopathy. To determinate whether JNK1 
regulates VEGF production, we analyzed its role in oxygen-induced retinopathy (OIR), a well established model of retinopathy of 
prematurity (ROP). In this model, when mouse pups are exposed to hyperoxia (75% oxygen) from postnatal day 7 to postnatal day 12 (from 
P7 to P12), vessel regression and cessation of normal radial vessel growth occur. Upon return to ambient air (normoxia) from P12 to P17, the 
non-perfused regions of the retina become hypoxic, resulting in expression of angiogenic factors, such as VEGF, and retinal 
neovascularization. Thus, litters of WT and Jnk1
-/-
 pups were placed under hyperoxia (75% oxygen) for 5 days on P7. After 5 days, on P12, 
mice were returned to ambient air until P17, when they were sacrificed, their eyes were enucleated and retinas were isolated. (A) Whole 
mounted retinas from mice exposed to hyperoxia followed by normoxia were stained with Alexa Fluor 594-conjugated B4 isolectin from 
Griffonia simplicifolia, which labels endothelial cells, and viewed by fluorescent microscopy. (B) Areas of vascular obliteration and 
neovascular tufts were quantified using at least 6 mice per genotype. Results are expressed as means ± s.e.m. *=p< 0.05 vs WT mice (C) 
Retinal proteins were extracted at P17 and VEGF was quantified by ELISA. Results are averages of two experiments using at least 6 mice 
per genotype. Results are expressed as means ± s.e.m. *=p< 0.05 vs control; #= p< 0.05 vs WT mice [19]. 
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report, deficient growth arrest DNA damage-ß (Gadd45ß) 
expression contributed to activation of JNK1/2, exacerbated 
clinical arthritis, and augmented joint destruction in passive 
K/BxN arthritis [86]. Gadd45ß, which is an NF-kB-regulated 
gene, was recently identified as an endogenous negative 
regulator of the JNK pathway because it blocks the upstream 
kinase MKK7 [87]. Gadd45ß deficiency permitted 
unregulated JNK activation by eliminating this endogenous 
negative feedback loop. Of particular relevance to RA, 
Gadd45ß expression is similar in rheumatoid synovium and 
OA tissue despite markedly higher NF-kB activation in the 
former [86] (see Fig. 4). Gadd45ß induction in cultured 
synoviocytes was also surprisingly low even when cells were 
activated with cytokines. These data suggest that high JNK 
activation in RA might be due, in part, to defective Gadd45ß 
expression and unregulated MKK7 function. 
 The role of JNK in single JNK1- or JNK2-deficient mice 
varies from model to model. JNK1 was found not to be 
essential for TNF-mediated joint disease [88]. Human TNF 
transgenic (hTNFtg) mice, which develop inflammatory 
arthritis, were intercrossed with JNK1-deficient mice. 
Histological and clinical analyses revealed no differences in 
the quantity of synovial inflammation and bone erosions or 
in the cellular composition of the synovial infiltrate. 
Moreover, cartilage damage, as indicated by proteoglycan 
loss in the articular cartilage, was comparable in the two 
strains. In other report, JNK2-deficient mice exhibited a 
modest decrease in bone and cartilage damage in passive 
collagen-induced arthritis but no difference in clinical benefit 
as determined by arthritis scores [26]. Levels of AP-1 
activation and MMP-13 gene expression were not decreased 
in JNK2-deficient mice, suggesting that additional signal 
transduction pathways, such as JNK1, might also regulate 
MMP in the joint, and could induce MMP-13 expression in 
the absence of JNK2. Some of these data suggest that both 
isoforms should be targeted for effective therapy. 
 We recently observed new roles of JNK1 in arthritis [62, 
89]. JNK1 and not JNK2 was critical for joint swelling and 
destruction in both the serum transfer model of arthritis 
(passive KxB/N) (see Fig. 5) and the antigen induced model 
of arthritis (AIA). The arthritogenic function of JNK1 was 
exerted in bone marrow derived cells, particularly mast cells 
in the passive KxB/N model and macrophages in the AIA 
model. Without JNK1, mast cells failed to degranulate 
Fig. (3). Kinetics of JNK pathway activation in joints of mice with passive K/BxN arthritis and collagen induced arthritis (CIA). The 
time course for JNK activation differs in two models of arthritis. Passive K/BxN arthritis is dependent only on innate immunity, while CIA 
involves both adaptive and innate immune mechanisms. (A) Clinical arthritis scores for passive K/BxN arthritis. (B) Clinical arthritis scores 
for CIA. (C and D) Phosphorylation of JNK and MKK4 were evaluated by Western blot analysis for passive K/BxN arthritis and CIA, 
respectively. Note that the time course for arthritis severity compared with JNK activation as well as JNK isoform activation differ in the two 
models [84]. 
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efficiently in some circumstances, and released much less 
IL-1. We also showed that without JNK1, the ability of 
macrophages to migrate was impaired, even in the presence 
of potent chemokine stimulation. Pharmacologic JNK 
inhibition effectively prevented arthritis onset and abrogated 
joint swelling in established disease in both models. Hence, 
JNK1 controls certain types of mast cell degranulation, and 
macrophage migration and might be therefore an attractive 
therapeutic target in inflammatory disorders. 
 JNK and apoptosis in RA. In RA, the synovial 
environment promotes survival of FLS and discourages their 
deletion through apoptosis [90]. NF-?B, which is highly 
activated in RA and lining cells, provides a strong pro-
survival signal linking inflammation and decreased apoptosis 
[91]. The p53 tumor suppressor, which can be mutated by 
the genotoxic synovial environment [92, 93], does not 
efficiently direct damaged synoviocytes to apoptosis. As 
mentioned, JNK may exert its anti-apoptotic function in p53-
deficient cells. Fas-dependent synoviocyte cell death is also 
inefficient, but it is dependent on JNK and AP-1 when it 
does occur [94]. 
 
 JNK and angiogenesis in RA. The observation that JNK 
plays a role in angiogenesis and especially VEGF expression 
implicates this kinase in maintaining the vasculature in 
inflamed synovium. Strategies to inhibit VEGF activity such 
as soluble VEGF-R1 or VEGF blocking antibodies reduce 
disease severity in murine CIA and the transgenic K/BxN 
mouse model of arthritis [95, 96]. In humans, these 
compounds have been administered to cancer patients, and 
VEGF or VEGFR inhibition has also been introduced to the 
treatment of neovascular eye diseases and recently also to 
arthritis trials [97, 98]. Inhibition of angiogenesis with a JNK 
inhibitor as a adjuvant therapy might therefore be of interest 
as treatment option for RA. 
 JNK and cell migration in RA. Migration of leukocytes 
into the synovium, which is partially regulated by the JNK 
pathway, is a multistep process involving interactions 
between leukocytes and endothelial cells and cellular 
adhesion molecules, as well as between leukocytes and 
chemokines and chemokine receptors. Synovial tissue and 
synovial fluid from RA patients contain increased 
concentrations of several chemokines such as monocyte  
 
 
Fig. (4). NF-?B activity and Gadd45? gene and protein expression in rheumatoid arthritis (RA) and osteoarthritis (OA) 
synovium. Gadd45ß is an NF-kB induced gene that suppresses the JNK pathway by binding to MKK7. Even though NF-kB activation is 
much higher in RA than OA, Gadd45ß expression is similar in the two diseases. Lack of Gadd45ß can contribute to over-activation of the 
JNK pathway in RA. (A-D), Immunohistochemical analyses of RA and OA synovium, showing Gadd45? protein expression (brown color) 
in RA synovial tissue (A) and OA synovial tissue (C), as well as staining for NF-?B in consecutive RA and OA sections (B and D, 
respectively) [86]. 
B 
C 
A 
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chemoattractant protein-4/CCL13, monokine induced by 
interferon-?/CXCL9, stromal cell-derived factor 1/CXCL12, 
monocyte chemotactic protein 1/CCL2, macrophage 
inflammatory protein 1?/CCL3, and fractalkine/CXC3CL1 
[99, 100]. Targeting individual chemokines through their 
receptors, such as CCR1 or CCR2, has met with limited 
success thus far [101, 102]. Given the role of JNK in 
chemokine signalling, chemotaxis, and cell migration, a 
strategy that targets the converging intrinsic mechanisms of 
macrophage migration in the MAPK pathway might be 
effective in inflammatory arthritis. 
 Upstream JNK kinases in RA. To identify potentially 
more inflammation-specific upstream
 
targets in the JNK 
MAPK pathways, synovial fibroblasts were
 
examined for 
expression and activation of MAPKKs and MAPKKKs that 
regulate JNK MAPK signaling was studied in FLS. 
Although MKK4
 
and MMK7 are activated by IL-1, only 
MKK7 is essential for IL-1-stimulated JNK activation and 
consequent c-Jun phosphorylation and AP-1 activation in 
synoviocytes. These data, especially in combination with the 
Gadd45ß studies, suggest that targeting of MKK7 could 
allow selective suppression of harmful pathogenic 
inflammation whilst leaving MKK4-mediated
 
activation of 
stress-related pathways intact [87]. 
 Even further more upstream, the MAPKKKs most 
relevant to JNK activation in synoviocytes have been 
identified [93]. Western blot analysis and qPCR 
demonstrated that TAK1, MEKK1, and MEKK2 are the 
most abundant MAP3Ks in cultured FLS. Surprisingly, the 
relatively JNK-specific MEKK4 was either not expressed or 
was present in very low levels. Using either small interfering 
RNA knockdown or knockout FLS, TAK1 deficiency 
significantly decreased P-JNK, P-MKK4 and P-MKK7 
induction but did not affect p38 activation. These results 
showed that TAK1 is a critical pathway for IL-1?-induced 
activation of JNK and JNK-regulated gene expression in 
FLS. In contrast to other cell lineages, MEKK1, MEKK2, 
and MEKK3 did not contribute to JNK phosphorylation in 
FLS after IL-1 stimulation. 
JNK AND PSORIATIC ARTHRITIS 
 There is a very little information on the activation of JNK 
and its upstream kinases in PsA. JNK is phosphorylated in 
the synovium of patients with PsA and is observed mainly in 
the intimal lining. Some sublining mononuclear cells and the 
perivascular compartment also contain P-JNK [103]. 
 Interestingly, an epidermis-specific, double knockout 
mouse lacking JunB and c-Jun, but not the single knockout, 
develops skin alterations that resemble lesions observed in 
patients with psoriasis [104]. As mentioned above, JNKs 
phosphorylate c-Jun very efficiently, although they do not 
phosphorylate JunB. The double-mutant mice showed a 
strong phenotype with inflamed plaques affecting primarily 
the ears, paws and tail, with a thickened epidermis, 
hyperkeratosis, and parakeratosis and increased 
subepidermal vascularization. Intraepidermal T cells, 
epidermal microabscesses and the typical inflammatory cell 
infiltrate consisting of neutrophils were seen together with 
increased numbers of macrophages in the dermis. Strikingly, 
arthritis strongly reminiscent of PsA was also observed with 
100% penetrance. Inflammatory infiltrates were present in 
the joint regions along with massive bone destruction and 
periostitis. Different manifestations of the disease, such as 
synovitis, dactylitis and enthesitis were also recognized. 
Increased expression of TNF and TNF-dependent cytokines 
contributed to disease development, as in the absence of 
TNFR1 the skin phenotype was improved and arthritis was 
prevented. 
JNK AND SYSTEMIC LUPUS ERYTHEMATOSUS 
 SLE is a systemic autoimmune disease associated with 
aberrant activation of T and B lymphocytes. Abnormal 
activation of intracellular signalling molecules in 
lymphocytes by inflammatory cytokines has been proposed 
as a trigger of the SLE inflammation. Several studies show 
high levels of JNK activation in peripheral lymphocytes in 
SLE patients [105]. The expression of active JNK in 
peripheral blood mononuclear cells significantly correlated 
with SLE disease activity index [106]. The data in SLE 
patients are also supported by data in murine models. In the 
parent-into-F(1) mouse model of lupus-like chronic graft-
versus-host disease (GVHD), increased JNK activation was 
observed in splenocyte from chronic GVHD mice [107]. 
Another study demonstrated over-expression of P-JNK in 
splenocytes from (NZBxNZW)F1 female mice with 
established lupus in comparison to disease-free mice, which 
correlated with a significantly higher T cell apoptosis [108]. 
However, additional data are needed to understand the 
function of high JNK kinase activity in SLE. 
 
Fig. (5). A pathogenic role for JNK1 in passive K/BxN serum transfer arthritis. Clinical arthritis scores and ankle swelling in WT (grey 
circles, n=15), Jnk1
-/-
 (black squares, n=15) and Jnk2
-/-
 mice (black circles, n=8) injected with 150 μl of K/BxN serum on day 0. Jnk1-/- mice 
develop less paw swelling than WT or Jnk2
-/-
 mice. Values are means ± SEM. * =p<0.05 vs WT or Jnk2
-/-
 mice by two way ANOVA [89]. 
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JNK IN OSTEOARTHRITIS 
 OA is characterized by degeneration of articular cartilage 
secondary to an imbalance between the synthesis and 
integration of ECM proteins and the degradation of both 
synthesized ECM proteins  [109]. Growth factors 
exemplified by insulin-like growth factor-1, its binding 
proteins and TGF-? contribute to anabolic pathways 
including compensatory biosynthesis of extracellular matrix 
proteins. Catabolic pathways are altered by cytokine genes 
such as IL-1 and TNF, which are expressed in OA synovium. 
In addition, IL-1 and TNF suppress ECM protein 
biosynthesis while concomitantly increasing MMP gene 
expression [35, 110]. Chondrocytes plays a central role in 
maintaining the cartilage homeostasis. The vitality of 
articular cartilage is also critical and it can be judged on the 
basis of the capacity of chondrocytes to resist apoptosis 
[111]. Thus, OA therapeutic strategies designed to modulate 
the imbalance between anabolic and catabolic pathways in 
OA might include neutralizing cytokine activity or MMP 
gene expression, or inhibiting signaling pathways that result 
in apoptosis [109]. 
 JNK inhibition could be a potential therapeutic candidate 
in OA as it plays a key role in cytokine production, MMP 
gene regulation and apoptosis. Surprisingly, there are little or 
no data of the role of JNK in animal models of OA. JNKs 
and the key upstream activators of JNK, MKK4 and MKK7, 
are expressed and activated in OA synovial tissues although 
their level activation is much less than in RA [17, 83]. JNKs 
are also expressed and activated in OA chondrocytes [112-
114]. Cytokines, such as IL-1 and TNF, but also 
compression and mechanical stimulation engages the JNK 
pathway in these cells. 
 Although JNKs regulate MMP expression in OA 
chondroctyes, proteases in the ADAMTS family appear to be 
more relevant to cartilage degradation in OA [115]. In a 
murine model of OA, there was a significant reduction in the 
severity of cartilage destruction in the ADAMTS5-deficient 
mice compared with wild type mice, suggesting that 
ADAMTS5 is the primary aggrecanase responsible for 
aggrecan degradation in OA [116]. Of interest, JNK also 
participates in ADAMTS regulation [117]. Further studies 
are needed to determine if JNK in chondrocytes regulates 
ADAMTS expression. 
 Apoptosis is also a possible pathogenic mechanism in 
OA [111, 118]. Osteoarthritis cartilage degeneration is 
largely a process of destruction and failure of the ECM. 
Anabolic activity, phenotypic stability, and finally, survival 
of the chondrocytes are essential for the maintenance of 
proper articular cartilage. Lacunar emptying is a typical 
feature of osteoarthritic cartilage and has led to the 
assumption that cell death is a central feature in cartilage 
degeneration. TNF, IL-1 and NO might contribute to 
induction of chondrocyte apoptosis [111, 118]. Several 
reports suggest that inhibiting JNK signaling in chondrocytes 
inhibits apoptosis induced by NO and could help preserve 
the cartilage extracellular matrix in OA [109, 119]. 
CONCLUSIONS 
 Despite the success of biological therapies in 
inflammatory arthritis, orally active small-molecule drugs 
are alternatives for patients with arthritis for whom 
conventional treatments have failed or who are unable to 
take biological agents. They might also be effective in other 
diseases such as OA, where the development of effective 
disease-modifying drugs is urgently needed. Small molecule 
inhibitors have been the focus of intense efforts, with some 
recent notable successes [120, 121] but also some failures 
such as selective p38? inhibitors that have limited efficacy 
[122]. Selective JNK1 inhibitor could reduce destructive 
inflammation in autoimmune disease, especially ones 
mediated by Th1 cells or mast cells. However, the general 
trend for greater and greater specificity might be 
counterproductive owing to the redundancy of signaling 
networks. As many JNK functions are redundant between 
JNK1 and JNK2, the inhibition of both JNK isoforms would 
likely have pluripotent effects, not only on hematopoietic 
cells but also on FLS, endothelial cells or chondrocytes, 
hence being more effective. The safety of signal transduction 
inhibitors needs to be carefully evaluated in non-oncologic 
indications. However, experience with a variety of 
compounds in rheumatoid arthritis, including those that 
target Syk, JAK, p38, MEK1/2, or c-Kit, suggest that the 
toxicity can be managed. Thus, inhibition of JNKs or less 
selective approaches that inhibit more than one kinase (e.g., 
combination JNK–p38 inhibitor) are reasonable possibilities 
for novel therapeutic agents. 
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